Vaccines against pandemic influenza

Viral Immunology

Volumn 20, Issue 2, 2007, Pages 326-327

  Dutton, Richard W ^a   Swain, Susan L ^a   Woodland, David L ^a  

^a TRUDEAU INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS HEMAGGLUTININ; VIRUS SIALIDASE;

ANTIBODY RESPONSE; CELLULAR IMMUNITY; DRUG EFFICACY; HOST RESISTANCE; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; NONHUMAN; PANDEMIC; REVIEW; VACCINE PRODUCTION;

ANIMALS; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; ORTHOMYXOVIRIDAE INFECTIONS; T-LYMPHOCYTES; VACCINES, ATTENUATED;

INFLUENZA A VIRUS;

EID: 34447517437     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2007.0011     Document Type: Review

References (9)

1. Brown DM, Dilzer AM, Meents DL, and Swain SL: CD4 T cell-mediated protection from lethal influenza: Perforin and antibody mediated mechanisms give a 1-2 punch. J Immunol 2006;177:2888-2898.
2. Epstein SL: Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: An experiment of nature. J Infect Dis 2006;193:49-53.
3. Frank AL, and Taber LH: Variation in frequency of natural reinfection with influenza A viruses. J Med Virol 1983; 12:17-23.
4. Liang S, Mozdzanowska K, Palladino G, and Gerhard W Hetero-subtypic immunity to influenza type A virus in mice Effector mechanisms and their longevity. J Immunol 1994; 152:1653-1661.
5. Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum LL, Rangarajan B, Newton DW, Boulton ML, and Monto AS: Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006;355:2513-2522.
6. Powell TJ, Strutt T, Reome J, Hollenbaugh JA, Roberts AD, Woodland DL, Swain SL, and Dutton RW: Priming with cold adapted influenza A does not prevent infection but elicits long lived protection against supralethal challenge with heterosubtypic virus. J Immunol 2007;178:1030-1038.
7. Sonoguchi T, Naito H, Hara M, Takeuchi Y, and Fukumi H: Cross-subtype protection in humans during sequential, overlapping, and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses. J Infect Dis 1985;151:81-88.
8. Steinhoff MC, Fries LF, Karron RA, Clements ML, and Murphy BR: Effect of heterosubtypic immunity on infection with attenuated influenza A virus vaccines in young children. J Clin Microbiol 1993;31:836-838.
9. Subbarao K, Murphy BR, and Fauci AS: Development of effective vaccines against pandemic influenza. Immunity 2006;24:5-9.